硬膜外类固醇注射中类固醇药物和稀释剂选择的趋势:脊柱介入协会医生的一项调查
Trends in steroid agent and diluent choices for epidural steroid injections: a survey of Spine Intervention Society physicians.
作者信息
Clements Nathan, Vydra Darrell, Cushman Daniel M, Nagpal Ameet, Julia Jonathan, Zheng Patricia, McCormick Zachary L
机构信息
Physical Medicine and Rehabilitation, UT Health San Antonio, San Antonio, Texas, USA
Physical Medicine and Rehabilitation, University of Texas Health Science Center at San Antonio Texas - Research Park Campus, San Antonio, Texas, USA.
出版信息
Reg Anesth Pain Med. 2019 May 24. doi: 10.1136/rapm-2018-100366.
BACKGROUND
Epidural steroid injections (ESIs) are a frequently used treatment for refractory radicular spinal pain. ESIs, particularly transforaminal epidural steroid injections (TFESI), may provide pain relief and delay the need for surgery. Corticosteroid agent and diluent choices are known to impact the safety of ESIs. In particular, the risk of embolization with particulate corticosteroids has led to recommendations for non-particulate steroid use by the Multisociety Pain Workgroup. Additionally, there is in vitro evidence that ropivacaine can crystalize in the presence of dexamethasone, potentially creating a particulate-like injectate. Despite widespread use and known risk mitigation strategies, current practice trends related to steroid and diluent choices are unknown.
OBJECTIVE
Identify the use of particulate versus non-particulate corticosteroids for epidural steroid injections in the cervical and lumbar spine, as well as local anesthetics commonly used as diluents during these procedures.
METHODS
Cross-sectional survey study of 314 physician members of the Spine Interventional Society.
RESULTS
41% and 9% of providers reported using particulate corticosteroids during lumbar TFESIs and cervical TFESI, respectively. Four per cent of providers reported the use of ropivacaine in cervical TFESIs. Forty-four per cent of respondents reported using anesthetic in cervical interlaminar ESIs. 21% of providers report using high volumes (> 4.5 mL) during cervical interlaminar ESIs.
CONCLUSION
Current trends, as assessed by this survey study, indicate substantial variability in steroid and diluent choice for ESIs. Patterns were identified that may impact patient safety including the continued use of particulate corticosteroids for TFESIs and the use of ropivacaine during TFESIs by a subset of respondents.
背景
硬膜外类固醇注射(ESI)是治疗难治性神经根性脊柱疼痛的常用方法。ESI,尤其是经椎间孔硬膜外类固醇注射(TFESI),可能会缓解疼痛并推迟手术需求。已知皮质类固醇药物和稀释剂的选择会影响ESI的安全性。特别是,颗粒状皮质类固醇栓塞的风险已导致多学会疼痛工作组建议使用非颗粒状类固醇。此外,有体外证据表明罗哌卡因在存在地塞米松的情况下会结晶,可能会形成类似颗粒的注射剂。尽管ESI广泛使用且有已知的风险缓解策略,但目前与类固醇和稀释剂选择相关的实践趋势尚不清楚。
目的
确定在颈椎和腰椎硬膜外类固醇注射中颗粒状与非颗粒状皮质类固醇的使用情况,以及这些操作中常用作稀释剂的局部麻醉剂。
方法
对脊柱介入协会的314名医师成员进行横断面调查研究。
结果
分别有41%和9%的医疗服务提供者报告在腰椎TFESI和颈椎TFESI期间使用颗粒状皮质类固醇。4%的医疗服务提供者报告在颈椎TFESI中使用罗哌卡因。44%的受访者报告在颈椎椎板间ESI中使用麻醉剂。21%的医疗服务提供者报告在颈椎椎板间ESI期间使用大容量(>4.5 mL)。
结论
通过这项调查研究评估的当前趋势表明,ESI的类固醇和稀释剂选择存在很大差异。已确定可能影响患者安全的模式,包括在TFESI中继续使用颗粒状皮质类固醇以及一部分受访者在TFESI期间使用罗哌卡因。